Community-Acquired Pneumonia: Disease Course Prediction With a 5-Gene Signature.

Background: Clinical decision-making for patients with community-acquired pneumonia (CAP) at risk of organ dysfunction and death is currently guided by clinical evaluation and scores. Every fifth patient with CAP requires admission to the ICU, with a subsequent high mortality; delayed admission to the ICU increases this risk. Research Question: Can a transcriptomic signature improve identification of at-risk patients compared with conventional scores and metrics? Study Design and Methods: Time-course transcriptomic data were obtained from blood samples taken from 455 participants in 41 centers enrolled in the Progression of Community-Acquired Pneumonia in the Hospital (PROGRESS) trial, a prospective observational cohort study of hospitalized patients with CAP who did not initially require organ support. Discovery (n = 240) and validation (n = 215) cohorts were randomly assigned. Transcriptome data were analyzed for association with a severe CAP course, defined as a composite of requirement for ICU admission or 28-day mortality. Predictive performance of the gene expression profiles was compared against clinical scores and serum markers, and validated in publicly available transcriptomic data sets. Results: A 5-gene signature consisting of Interpretation: We identified a 5-gene transcriptomic signature that, taken soon after hospital admission, was shown to predict disease course of hospitalized patients with CAP. STYCK was superior to conventional, currently used scores and clinical metrics in predicting this deterioration and improved, if added to the Sequential Organ Failure Assessment, its performance. Clinical Trial Registration: ClinicalTrials.gov; No.: NCT02782013; URL: www.clinicaltrials.gov.